Claims for Patent: 7,659,253

Summary for Patent: 7,659,253

Title:	Abuse-resistant amphetamine prodrugs
Abstract:	The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s):	Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US12/131,923
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,659,253
Patent Claims:	1. Crystalline lisdexamphetamine dimesylate. 2. The crystalline lisdexamphetamine dimesylate of claim 1, wherein the crystalline lisdexamphetamine dimesylate exhibits an X-ray powder diffraction pattern substantially as shown in FIG. 77. 3. The crystalline lisdexamphetamine dimesylate of claim 1, wherein the crystalline lisdexamphetamine dimesylate exhibits an X-ray powder diffraction pattern having at least one peak in degrees 2Θ±0.2 2Θ selected from 4.5, 9.0, 12.0, 15.7, and 16.3. 4. The crystalline lisdexamphetamine dimesylate of claim 3, wherein the dimesylate exhibits an X-ray powder diffraction pattern having at least two peaks in degrees 2Θ±0.2 2Θ selected from 4.5, 9.0, 12.0, 15.7, and 16.3. 5. The crystalline lisdexamphetamine dimesylate of claim 4, wherein the dimesylate exhibits an X-ray powder diffraction pattern having peaks in degrees 2Θ±0.2 2Θ at 4.5, 9.0, 12.0 and 15.7. 6. The crystalline lisdexamphetamine dimesylate of claim 1, wherein the crystalline lisdexamphetamine dimesylate has a melting point onset as determined by differential scanning calorimetry at about 194.7° C. 7. The crystalline lisdexamphetamine dimesylate of claim 1, wherein the crystalline lisdexamphetamine dimesylate exhibits a single crystal X-ray crystallographic analysis at 150 K with crystal parameters that are approximately equal to the following: Parameter Value Space group P21/a Cell Dimensions a (Å) 10.25 b (Å) 11.28 c (Å) 19.35 β(°) 94.12 Volume (Å3) 2232.1 Z (Molecules/unit cell) 4 Density (g/cm3) 1.359. 8. Crystalline lisdexamphetamine dimesylate particles having at least one of: (a) a d10 ranging from about 1 to about 10 μm; (b) a d50 ranging from about 8 to about 40 μm; and (c) a d50 particle size ranging from about 25 to about 90 μm. 9. The crystalline lisdexamphetamine dimesylate particles of claim 8, wherein the crystalline lisdexamphetamine dimesylate has a d90 particle size ranging from about 25 to about 90 μm. 10. The crystalline lisdexamphetamine dimesylate particles of claim 8, wherein the crystalline lisdexamphetamine dimesylate has a d50 ranging from about 8 to about 40 μm. 11. A pharmaceutical composition comprising crystalline lisdexamphetamine dimesylate of claim 1 and a pharmaceutically acceptable additive. 12. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition comprises at least about 95% by weight of crystalline lisdexamphetamine dimesylate, based upon 100% total weight of lisdexamphetamine dimesylate in the pharmaceutical composition. 13. A method of treating attention deficit hyperactivity disorder in a patient in need thereof, comprising the step of orally administering crystalline lisdexamphetamine dimesylate.